Is there a better answer coming to oncology therapeutics? Using targeted molecule therapies, a broader base of patients may be found. Press play to learn: How John Mulligan came to Good Therapeutics The impact of tumor-specific T-cells Other cytokines that can be effective treatments John Mulligan, the CEO at Good Therapeutics, shares his work developing targeted molecular therapies for a variety of applications. Genetics can be a surprisingly strong tool in modeling and developing a novel drug. However, the applications can be fairly limited since the patient base can be only a percentage of folks compared to other traditional therapeutics. One of the most promising new developments is the use of Cytokines to treat and combat many forms of cancer. The hope is to expand the application to a broader base of patients moving forward.  Visit https://goodtherapeutics.com for more information. This episode is sponsored by SOTA CBD. To receive a 25% discount at checkout, use the code FINDINGGENIUS at checkout. Go to sotacbd.com to shop now! Episode also available on Apple Podcast: http://apple.co/30PvU9C